I have felt that way but it isn't in the mindset of investors until it becomes obvious there is clinical success at other companies with the type of drug or molecular target...etc....In the late 90's say 1998-early 1999 PDLI got crushed just before a euphoric 20 fold pop on the belief their MA humanization patents were worth billions instead of $100-150 million tech value march 1999. They were signing licencing deals and getting paid for them and were involved interestingly in European patent challenges by IDEC among others. Did Simmons say this 2 years ago...IE when there was a little less dilution? I think some clinical success @ Lilly would go along way to justifying COR's IP value above the current price.....
Market Data 
Markets 
AI
